Detailed information for compound 1566520
Basic information
Technical information
- Name: Unnamed compound
- MW: 503.548 | Formula: C26H22FN5O3S
-
H donors: 2
H acceptors: 5
LogP: 4.06
Rotable bonds: 7
Rule of 5 violations (Lipinski): 2 - SMILES: CNC(=O)c1ccc(cc1F)c1ccc2c(n1)Oc1c([C@@H]2C(C(=O)Nc2scnn2)(C)C)cccc1
- InChi: 1S/C26H22FN5O3S/c1-26(2,24(34)31-25-32-29-13-36-25)21-16-6-4-5-7-20(16)35-23-17(21)10-11-19(30-23)14-8-9-15(18(27)12-14)22(33)28-3/h4-13,21H,1-3H3,(H,28,33)(H,31,32,34)/t21-/m0/s1
- InChiKey: DKPAXGCEBPPSRC-NRFANRHFSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Trichomonas vaginalis | conserved hypothetical protein | 0.0195 | 1 | 0.5 |
| Leishmania major | macrophage migration inhibitory factor-like protein | 0.0195 | 1 | 0.5 |
| Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0155 | 0.6438 | 0.6438 |
| Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0155 | 0.6438 | 0.5 |
| Echinococcus granulosus | acetylcholinesterase | 0.0155 | 0.6438 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0155 | 0.6438 | 0.6438 |
| Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | 0.0174 | 0.812 | 0.5 |
| Loa Loa (eye worm) | carboxylesterase | 0.0155 | 0.6438 | 0.6438 |
| Trichomonas vaginalis | macrophage migration inhibitory factor, mif, putative | 0.0195 | 1 | 0.5 |
| Giardia lamblia | Macrophage migration inhibitory factor | 0.0195 | 1 | 0.5 |
| Leishmania major | macrophage migration inhibitory factor-like protein | 0.0195 | 1 | 0.5 |
| Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | 0.0174 | 0.812 | 0.5 |
| Echinococcus granulosus | carboxylesterase 5A | 0.0155 | 0.6438 | 0.5 |
| Echinococcus multilocularis | acetylcholinesterase | 0.0155 | 0.6438 | 0.5 |
| Mycobacterium tuberculosis | Probable flavin-containing monoamine oxidase AofH (amine oxidase) (MAO) | 0.0162 | 0.7024 | 0.5 |
| Echinococcus multilocularis | carboxylesterase 5A | 0.0155 | 0.6438 | 0.5 |
| Echinococcus multilocularis | acetylcholinesterase | 0.0155 | 0.6438 | 0.5 |
| Loa Loa (eye worm) | macrophage migration inhibitory factor | 0.0195 | 1 | 1 |
| Plasmodium vivax | macrophage migration inhibitory factor, putative | 0.0195 | 1 | 0.5 |
| Entamoeba histolytica | macrophage migration inhibitory factor-like protein | 0.0195 | 1 | 0.5 |
| Toxoplasma gondii | macrophage migration inhibitory factor, putative | 0.0195 | 1 | 0.5 |
| Echinococcus granulosus | acetylcholinesterase | 0.0155 | 0.6438 | 0.5 |
| Plasmodium falciparum | macrophage migration inhibitory factor | 0.0195 | 1 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0155 | 0.6438 | 0.6438 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| EC50 (binding) | = 34.1 nM | Transrepression activity at glucocorticoid receptor alpha in phorbol myristate acetate-stimulated human A549 cells assessed as inhibition of AP1 response element by luciferase reporter gene assay | ChEMBL. | 21899328 |
| EC50 (binding) | = 157 nM | Transrepression activity at glucocorticoid receptor alpha in IL-1beta-stimulated human A549 cells assessed as inhibition of NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay | ChEMBL. | 21899328 |
| EC50 (binding) | = 408 nM | Transactivation activity at GR-alpha in human NP1 Hela cells assessed as inhibition of GAL4-DBD after 20 hrs by luciferase reporter gene assay | ChEMBL. | 21899328 |
| EC50 (functional) | = 819 nM | Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced TNFalpha production after overnight incubation by ELISA | ChEMBL. | 21899328 |
| EC50 (binding) | > 5000 nM | Transactivation activity at glucocorticoid receptor alpha human 13D3/Huh7 cells assessed as induction of TAT activity after 4 hrs by spectrophotometry | ChEMBL. | 21899328 |
| EC50 (binding) | > 10000 nM | Transactivation activity at GR-alpha in human NP1 Hela cells assessed as induction of GAL4-DBD after 20 hrs by luciferase reporter gene assay | ChEMBL. | 21899328 |
| EC50 (functional) | > 20000 nM | Antiinflammatory activity in human whole blood assessed as inhibition of TNF-alpha-induced IL-8 production after overnight incubation by ELISA | ChEMBL. | 21899328 |
| EC50 (functional) | > 20000 nM | Antiinflammatory activity in human whole blood assessed as inhibition of IL-1beta-induced IL-8 production after overnight incubation by ELISA | ChEMBL. | 21899328 |
| Emax (binding) | = 0.3 % | Transactivation activity at GR-alpha in human NP1 Hela cells assessed as induction of GAL4-DBD after 20 hrs by luciferase reporter gene assay relative to Dexamethasone | ChEMBL. | 21899328 |
| Emax (binding) | = 20 % | Transactivation activity at glucocorticoid receptor alpha human 13D3/Huh7 cells assessed as induction of TAT activity after 4 hrs by spectrophotometry relative to Dexamethasone | ChEMBL. | 21899328 |
| Emax (binding) | = 26 % | Transrepression activity at glucocorticoid receptor alpha in IL-1beta-stimulated human A549 cells assessed as inhibition of NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay relative to Dexamethasone | ChEMBL. | 21899328 |
| Emax (binding) | = 38 % | Transrepression activity at glucocorticoid receptor alpha in phorbol myristate acetate-stimulated human A549 cells assessed as inhibition of AP1 response element by luciferase reporter gene assay relative to Dexamethasone | ChEMBL. | 21899328 |
| Imax (functional) | = 15 % | Antiinflammatory activity in human whole blood assessed as inhibition of TNF-alpha-induced IL-8 production after overnight incubation by ELISA relative to dexamethasone | ChEMBL. | 21899328 |
| Imax (functional) | = 35 % | Antiinflammatory activity in human whole blood assessed as inhibition of IL-1beta-induced IL-8 production after overnight incubation by ELISA relative to Dexamethasone | ChEMBL. | 21899328 |
| Imax (functional) | = 58 % | Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced TNFalpha production after overnight incubation by ELISA relative to Dexamethasone | ChEMBL. | 21899328 |
| Imax (binding) | = 102 % | Transactivation activity at GR-alpha in human NP1 Hela cells assessed as inhibition of GAL4-DBD after 20 hrs by luciferase reporter gene assay in presence of 100 nM Dexamethasone | ChEMBL. | 21899328 |
| Ki (binding) | = 5.48 nM | Displacement of GS-red from glucocorticoid receptor by fluorescence polarization assay | ChEMBL. | 21899328 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Homo sapiens | ChEMBL23 | 21899328 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL1911269
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.